This study is currently not recruiting participants.

GOG-0283; A Phase II Trial of DCTD-Sponsored Dasatinib (NSC #732517 IND #120636) In Recurrent/Persistent Ovary Fallopian Tube Primary Peritoneal and Endometrial Clear Cell Carcinoma Characterized for the Retention or Loss of BAF250a Expression

Study on the Effectiveness of Investigational Medication for Persistent Gynecologic Cancers

Not Recruiting
18 years - 100 years
Female
Phase N/A
1 Location

Brief description of study.

This phase II trial studies how well dasatinib works in treating patients with persistent ovarian, fallopian tube, endometrial, or peritoneal cancer. Dasatinib may shrink patients' tumors by blocking some of the enzymes needed for cell growth.

Detailed description of study

The purpose of this study is to test any good and bad effects of the study drug call Dasatnib on subjects with recurrent ovary, fallopian tube, primary peritoneal, and endometrial clear cell carcinoma.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: ovarian cancer,fallopian tube cancer,endometrial cancer
  • Age: 18 years - 100 years
  • Gender: Female

This study investigates how well an investigational medication works in treating patients with persistent ovarian, fallopian tube, endometrial, or peritoneal cancer. These are types of cancer that occur in the female reproductive organs or the lining of the abdomen. The purpose of this study is to test the effects of the investigational medication on these types of recurrent cancers.

Participants will receive the investigational medication to understand its effects on their cancer. The study will monitor any good or bad effects the medication may have on the patients' tumors, which may involve blocking certain enzymes needed for cancer cell growth.

  • Who can participate: Eligible participants are adults aged 18 and over with a diagnosis of persistent ovarian, fallopian tube, endometrial, or peritoneal cancer. Participants should not have any other serious health conditions that would interfere with the study's procedures.
  • Study details: Participants will take the investigational medication as part of the study. The effects on their cancer will be closely monitored to see if the medication blocks enzymes needed for cancer cell growth.
Updated on 19 Feb 2024. Study ID: 1409294744

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team